Kite Pharma, Inc.   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Santa Monica CA United States (2009)
Status: Acquired by Gilead Sciences (2017)

Organization Overview

First Clinical Trial
2015
NCT02348216
First Marketed Drug
2017
axicabtagene ciloleucel (Yescarta)
First NDA Approval
2017
axicabtagene ciloleucel (Yescarta)
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Kite Pharma | Kite Pharma Inc. | Kite Systems

Active Ingredients

Marketed Drugs (1)

axicabtagene ciloleucel (Yescarta) (2017 NDA)

Drugs in Phase 2 Trials (3)

Key: Kite Pharma, Inc. (2) Acquired (1)

atezolizumab (Tecentriq) (1 trial)

axicabtagene ciloleucel (Yescarta) (8 trials)

tmpsma-02 (1 trial)

Drugs in Phase 1 Trials (9)

Key: Kite Pharma, Inc. (3) Acquired (6)

cannabis (1 trial)

cart-egfr-il13ra2 (1 trial)

cart-psma-tgfbetardn cells (1 trial)

cyclophosphamide (cytoxan) (3 trials)

dasatinib (sprycel) (1 trial)

fludarabine (fludara) (3 trials)

gpc2 car t cells (1 trial)

kite-718 (1 trial)

muc1 car-t cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Marijuana Abuse (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 16
  • # of Trial APIs: 12